ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 99 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $578,000 | -42.4% | 28,971 | -49.4% | 0.02% | -40.0% |
| Q1 2018 | $1,003,000 | -25.6% | 57,300 | +4.8% | 0.04% | -33.3% |
| Q4 2017 | $1,348,000 | +110.6% | 54,700 | +131.8% | 0.06% | +76.5% |
| Q2 2017 | $640,000 | +88.8% | 23,600 | +107.0% | 0.03% | +112.5% |
| Q1 2017 | $339,000 | +4.3% | 11,400 | -5.0% | 0.02% | -15.8% |
| Q4 2016 | $325,000 | – | 12,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |